SENS — Senseonics Holdings, Inc.

Senseonics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $14.3 million, a 72% increase from $8.3 million in Q4 2024.
• Full-Year 2025 Revenue: $35.3 million, up from $22.5 million in 2024, representing approximately 60% year-over-year growth.
• U.S. Revenue: $27.9 million for the full year, compared to $15.3 million in 2024.
• Gross Profit: $7.7 million in Q4, with gross margins improving to over 50% for the year.
• Net Loss: $20.8 million in Q4 ($0.46 loss per share), up from a loss of $15.5 million in Q4 2024. Full-year net loss was $69.1 million, a decrease from $78.6 million in 2024.
• Cash Position: As of December 31, 2025, cash and equivalents totaled $94.3 million.

2. Strategic Updates and Business Highlights

• Commercial Transition: Senseonics successfully transitioned all commercial activities from Ascensia Diabetes Care back in-house, enhancing operational control and eliminating revenue sharing.
• Product Launches: Eversense 365 is now approved in both the U.S. and EU, with a dedicated European sales force expected to launch in Q2 2026.
• Patient Growth: The number of patients using Eversense in the U.S. doubled, with new patient starts increasing by 103% in 2025.
• DTC Marketing: A revamped direct-to-consumer marketing strategy significantly contributed to growth, with plans to invest $12 million to $15 million in 2026, distributed more evenly throughout the year.
• Partnerships: Integration with Sequel's twiist insulin delivery system marks a significant milestone, allowing seamless glucose monitoring for patients.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $58 million and $62 million, reflecting growth of 65% to 76% year-over-year.
• Gross Margin Expectations: Anticipated to remain above 50% as the company transitions to a fully integrated commercial model.
• Operating Expenses: Projected to be between $150 million and $160 million in 2026, reflecting increased spending on sales and marketing as well as R&D for upcoming products.
• Patient Retention: Early retention rates for the Eversense 365 sensor are in line with expectations, with a goal to double the patient base again in 2026.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The net loss widened in Q4 2025 compared to the previous year, primarily due to higher sales commissions and operational costs associated with the transition.
• Seasonality: The business is seasonal, with Q1 typically being weaker due to insurance deductible resets, which could impact early 2026 revenue.
• Operational Transition in Europe: While the U.S. transition was smooth, the European transition is more complex and may face hurdles related to local purchase agreements and tender processes.

5. Notable Q&A Insights

• New Patient Starts: Early 2026 has shown continued strong interest in new patient starts, particularly with the Sequel partnership, despite typical seasonal slowdowns.
• Commercial Transition Success: The transition from Ascensia was described as seamless, with nearly all sales reps moving to Senseonics without customer impact.
• DTC Strategy: The company is refining its DTC marketing approach based on last year's learnings, focusing on geographic targeting and optimizing ad spend.
• Prescriber Base Growth: The active prescriber base grew by over 80% year-over-year, and there is optimism about further growth with the in-house commercial team.
• Future Partnerships: While there is interest in additional pump partnerships, no new agreements have been announced yet, and these are not factored into current revenue guidance.

Overall, Senseonics demonstrated strong growth in 2025 with significant strategic shifts and product advancements, while also facing challenges related to operational transitions and seasonal revenue patterns.